Thank you to our speakers, sponsors, and delegates who joined us in Boston for the Viral Vector Characterization & Analytical Development Summit! If you are interested in the 2024 event, please get in touch at info@hansonwade.com
Redefine CQAs & Optimize Process Development with Fit-for-Purpose Analytics for Best-in-Class Product Quality
September 25-27 | Boston, MA
The Only Industry-Led Summit Dedicated to Accelerating Viral Vector Characterization & Analytical Development for Cell, Gene & Vaccine Therapies
In 2023, the industry is witnessed a renaissance in viral vector characterization. Spurred by widespread biopharma investment to engineer a new wave of novel capsids and faced with newly launched QbD frameworks by US Pharmacopeia and the FDA’s tightened guidance, the increased vector complexity is creating a new era for advanced analytical technologies to ensure precision and accuracy.
In the wake of significant collaborations including Vector Bio and iBET’s for high-throughput characterization, and the likes of Vertex and BMS announcing their priority to build out their internal analytical competencies, the inaugural Viral Vector Characterization & Analytical Development Summit arrived to pave the foundation for teams to further optimize process development and accelerate vector scale-up with GMP compliance in mind.
Uniting Characterization, Analytical, Formulation, Quality, Engineering, CMC and Process leaders, this industry-led summit was your only conference for cross-learning opportunities across AAV’s, LV’s & RV’s and more – so you could benchmark your work against rapid-analytical method development transforming your peers’ workflows, turnaround, and consistency.
Attendees stayed ahead of the curve, and joined the likes of Ultragenyx, Kite Pharma, BioMarin, Neogene Therapeutics, Pfizer and many more for a 3-day jam packed agenda, that tackled the biggest bottlenecks in:
Developing phase appropriate potency assays and packages to demonstrate specificity, sensitivity and accuracy of results to enable improved efficacy
Navigating the regulatory agencies’ expectation and define predictive CQA’s to provide sufficient data during IND for smooth approval process
Leveraging analytics to enhance process development and formulation capabilities to protect final product safety
Applying advanced analytical technologies and interpret datapoints effectively to streamline development and align analytics with programs scaling up quickly
Establishing novel characterization and analytical methods with rapid, precise and accurate results to deepen your understanding of your capsid biology, improve encapsulation efficiency, protect stability and minimize impurities
The one-stop-shop to build out analytical capabilities and characterization package, attendees joined 60+ technical leaders to gain practical takeaways improving analytical capabilities so critical to process development and ensuring quality for patients.
Companies in Our Event Series Community:
2023 World-Class Speaker Faculty:
2023 Partner
What You Missed:
16+
Industry & Academic Presenters
3
Jam-Packed Days of Exclusive Content
60+
Viral Vector Delivery Leader Attendees
2
Deep Dive & Collaborative Workshops
Our Viral Vector Meeting Series Attendees Said:
“Well organized event covering important topics for viral vector manufacturing and analytics. High-quality presentations and engaged audiences.”
Director & Head of Viral Vector, R&D, Lonza
“I enjoyed the people, their expertise, and their willingness to speak about their experiences and issues facing the field..”
Senior Scientist, Viral Vector Process Development, Bristol Myers Squibb
“Good cross section of industry willing to discuss details.”
Senior Director of Process Science and Head of Vector Core, Affinia Therapeutics
